What is Titan Pharmaceut's earnings per share (EPS)?

Titan Pharmaceut (TTNP) reported diluted earnings per share of $-5.23 for fiscal year 2024. This represents a 29.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Titan Pharmaceut Financials

TTNP

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2025 Currency USD FYE December

This page shows Titan Pharmaceut (TTNP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TTNP FY2024 2026-04-22

Titan’s visible business mechanic is cash runway management, with minimal operating assets supporting a company still financed more by past equity than by sales.

From FY2023 to FY2024, operating cash burn improved from -$7.1M to -$3.9M. But cash still fell to $2.8M after the prior year’s $10.0M financing inflow disappeared, which implies the smaller loss came from a reduced operating footprint rather than a business that now funds itself.

In FY2024, SG&A effectively equaled the operating loss at $4.6M, while reported R&D spending dropped out of the cost structure. That points to a company spending mainly to maintain the corporate platform, not to support a broad revenue engine or an expanding development program.

The balance sheet is liquid but thin, with cash of $2.8M against only $483K of liabilities. A 6.1x current ratio means near-term strain is less about debt coming due and more about how long a small cash reserve can continue absorbing recurring overhead.

Financial Health Signals

Financial health score pending refresh

We are recalculating Titan Pharmaceut's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Titan Pharmaceut passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.82x

For every $1 of reported earnings, Titan Pharmaceut generates $0.82 in operating cash flow (-$3.9M OCF vs -$4.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$4.6M

YoY+36.5%

Titan Pharmaceut's EBITDA was -$4.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 36.5% from the prior year.

Net Income

-$4.7M

YoY+15.5%

Titan Pharmaceut reported -$4.7M in net income in fiscal year 2024. This represents an increase of 15.5% from the prior year.

EPS (Diluted)

$-5.23

YoY+29.4%

Titan Pharmaceut earned $-5.23 per diluted share (EPS) in fiscal year 2024. This represents an increase of 29.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$2.8M

YoY-58.1%

5Y CAGR-11.5%

10Y CAGR-15.6%

Titan Pharmaceut held $2.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

914,234

YoY+17.0%

Titan Pharmaceut had 914,234 shares outstanding in fiscal year 2024. This represents an increase of 17.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-192.9%

YoY-109.0pp

5Y CAGR+955.6pp

10Y CAGR-165.0pp

Titan Pharmaceut's ROE was -192.9% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 109.0 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

TTNP Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	$184K-67.0%	$557K-63.5%	$1.5M-68.5%	$4.8M+85.7%	$2.6M
Cost of Revenue	N/A	N/A	N/A	$199K-57.8%	$472K	$0
Gross Profit	N/A	N/A	N/A	$1.3M-69.6%	$4.4M+67.6%	$2.6M
R&D Expenses	N/A	$1.9M-59.8%	$4.8M-16.4%	$5.7M-3.8%	$5.9M+16.5%	$5.1M
SG&A Expenses	$4.6M-17.9%	$5.5M-8.1%	$6.0M+20.9%	$5.0M-14.0%	$5.8M-51.4%	$11.9M
Operating Income	-$4.6M+37.4%	-$7.3M+28.9%	-$10.2M-9.4%	-$9.4M-27.2%	-$7.4M+6.7%	-$7.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$1K0.0%	$1K+125.0%	-$4K	$0	$0	$0
Net Income	-$4.7M+15.5%	-$5.6M+45.4%	-$10.2M-16.3%	-$8.8M+51.9%	-$18.2M-10.8%	-$16.5M
EPS (Diluted)	$-5.23+29.4%	$-7.41+51.2%	$-15.19	$-0.90+54.1%	$-1.96	$-0.72

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$4K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$424K
SG&A Expenses	$657K+23.0%	$534K	N/A	$754K-63.6%	$2.1M+95.1%	$1.1M	N/A	$1.6M
Operating Income	-$657K-23.0%	-$534K	N/A	-$754K+63.6%	-$2.1M-95.1%	-$1.1M	N/A	-$2.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$689K-22.4%	-$563K	N/A	-$763K+63.5%	-$2.1M-97.5%	-$1.1M	N/A	-$338K
EPS (Diluted)	$-0.65-4.8%	$-0.62	N/A	$-0.83+63.8%	$-2.29-84.7%	$-1.24	N/A	$-0.45

TTNP Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$2.9M-63.9%	$8.1M+99.3%	$4.1M-49.2%	$8.0M-1.1%	$8.1M-15.1%	$9.5M
Current Assets	$2.9M-63.5%	$8.0M+122.5%	$3.6M-50.2%	$7.2M-1.4%	$7.3M-11.8%	$8.3M
Cash & Equivalents	$2.8M-58.1%	$6.8M+130.2%	$2.9M-51.4%	$6.0M+11.5%	$5.4M+3.6%	$5.2M
Inventory	N/A	$0-100.0%	$106K-63.8%	$293K-10.7%	$328K-41.7%	$563K
Accounts Receivable	N/A	$46K+27.8%	$36K-67.9%	$112K-87.3%	$884K+101.8%	$438K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$483K-66.6%	$1.4M-46.4%	$2.7M-5.6%	$2.9M-37.3%	$4.6M-43.7%	$8.1M
Current Liabilities	$483K-66.6%	$1.4M-45.1%	$2.6M-1.5%	$2.7M-36.8%	$4.2M+17.3%	$3.6M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$332K-91.7%	$4.0M
Total Equity	$2.4M-63.3%	$6.6M+387.3%	$1.4M-73.5%	$5.1M+45.5%	$3.5M+146.5%	$1.4M
Retained Earnings	-$396.5M-1.2%	-$391.8M-1.4%	-$386.3M-2.7%	-$376.1M-2.4%	-$367.3M-5.2%	-$349.0M

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$3.1M+41.5%	$2.2M-26.2%	$2.9M-18.9%	$3.6M-17.2%	$4.3M-34.5%	$6.6M-17.8%	$8.1M-19.1%	$10.0M
Current Assets	$3.1M+41.5%	$2.2M-26.2%	$2.9M-18.9%	$3.6M-17.2%	$4.3M-34.2%	$6.6M-17.5%	$8.0M-19.0%	$9.9M
Cash & Equivalents	$2.8M+44.1%	$1.9M-31.3%	$2.8M-16.7%	$3.4M-16.9%	$4.1M-33.6%	$6.2M-8.9%	$6.8M-16.5%	$8.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Accounts Receivable	N/A	N/A	N/A	$38K0.0%	$38K-71.6%	$134K+191.3%	$46K+76.9%	$26K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$263K-5.7%	$279K-42.2%	$483K+30.2%	$371K+4.2%	$356K-36.3%	$559K-61.3%	$1.4M-22.6%	$1.9M
Current Liabilities	$263K-5.7%	$279K-42.2%	$483K+30.2%	$371K+4.2%	$356K-36.3%	$559K-61.3%	$1.4M-22.6%	$1.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.8M+48.5%	$1.9M-23.1%	$2.4M-24.5%	$3.2M-19.1%	$4.0M-34.4%	$6.1M-8.4%	$6.6M-18.3%	$8.1M
Retained Earnings	-$397.8M-0.2%	-$397.1M-0.1%	-$396.5M-0.2%	-$395.7M-0.2%	-$395.0M-0.5%	-$392.9M-0.3%	-$391.8M-0.4%	-$390.3M

TTNP Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$3.9M+45.3%	-$7.1M+13.3%	-$8.2M-3.6%	-$7.9M+54.1%	-$17.2M-11.4%	-$15.4M
Capital Expenditures	N/A	$2K	N/A	$23K-95.7%	$540K+110.9%	$256K
Free Cash Flow	N/A	-$7.1M	N/A	-$7.9M+55.4%	-$17.7M-13.0%	-$15.7M
Investing Cash Flow	N/A	$732K	N/A	-$23K+95.7%	-$540K-110.9%	-$256K
Financing Cash Flow	-$62K-100.6%	$10.0M+100.6%	$5.0M-43.6%	$8.8M-50.7%	$17.9M+59.1%	$11.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$680K+21.6%	-$867K-71.3%	-$506K+27.0%	-$693K+66.5%	-$2.1M-237.4%	-$613K	N/A	-$1.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$1.5M+8194.7%	-$19K	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TTNP Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	87.0%-3.3pp	90.2%-9.8pp	100.0%
Operating Margin	N/A	-3954.9%-2117.4pp	-1837.5%-1224.5pp	-613.0%-461.0pp	-151.9%+150.4pp	-302.3%
Net Margin	N/A	-3026.6%-1194.3pp	-1832.3%-1257.2pp	-575.1%-198.0pp	-377.1%+254.7pp	-631.8%
Return on Equity	-192.9%-109.0pp	-83.9%+664.9pp	-748.8%-578.0pp	-170.8%+345.7pp	-516.5%+632.0pp	-1148.5%
Return on Assets	-161.0%-92.1pp	-68.9%+182.6pp	-251.5%-141.7pp	-109.8%+115.8pp	-225.6%-52.7pp	-172.8%
Current Ratio	6.05+0.5	5.55+4.2	1.37-1.3	2.71+1.0	1.74-0.6	2.31
Debt-to-Equity	0.20-0.0	0.22-1.8	1.98+2.0	0.00-0.1	0.09-2.7	2.80
FCF Margin	N/A	-3855.4%	N/A	-519.1%-152.4pp	-366.7%+236.0pp	-602.7%

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-51525.0%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-8450.0%
Return on Equity	-24.7%+5.3pp	-30.0%	N/A	-23.6%+28.8pp	-52.4%-35.0pp	-17.4%	N/A	-4.2%
Return on Assets	-22.6%+3.5pp	-26.1%	N/A	-21.2%+26.9pp	-48.1%-32.2pp	-16.0%	N/A	-3.4%
Current Ratio	11.60+3.9	7.73+1.7	6.05-3.7	9.71-2.5	12.22+0.4	11.83+6.3	5.55+0.2	5.30
Debt-to-Equity	0.09-0.1	0.15-0.0	0.20+0.1	0.11+0.0	0.090.0	0.09-0.1	0.22-0.0	0.23
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

60 degrees pharmaceuticals, Inc. SXTP

$4.1M

Polyrizon Ltd PLRZ

$30.5M

Ensysce Biosciences Inc ENSC

$4.1M

Pasithea Therapeutics Corp KTTA

$16.5M

Palisade Bio Inc PALI

$340.6M

Frequently Asked Questions

Is Titan Pharmaceut profitable?

No, Titan Pharmaceut (TTNP) reported a net income of -$4.7M in fiscal year 2024.

What is Titan Pharmaceut's EBITDA?

Titan Pharmaceut (TTNP) had EBITDA of -$4.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Titan Pharmaceut's return on equity (ROE)?

Titan Pharmaceut (TTNP) has a return on equity of -192.9% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Titan Pharmaceut's operating cash flow?

Titan Pharmaceut (TTNP) generated -$3.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Titan Pharmaceut's total assets?

Titan Pharmaceut (TTNP) had $2.9M in total assets as of fiscal year 2024, including both current and long-term assets.

How many shares does Titan Pharmaceut have outstanding?

Titan Pharmaceut (TTNP) had 914,234 shares outstanding as of fiscal year 2024.

What is Titan Pharmaceut's current ratio?

Titan Pharmaceut (TTNP) had a current ratio of 6.05 as of fiscal year 2024, which is generally considered healthy.

What is Titan Pharmaceut's debt-to-equity ratio?

Titan Pharmaceut (TTNP) had a debt-to-equity ratio of 0.20 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Titan Pharmaceut's return on assets (ROA)?

Titan Pharmaceut (TTNP) had a return on assets of -161.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Titan Pharmaceut's cash runway?

Based on fiscal year 2024 data, Titan Pharmaceut (TTNP) had $2.8M in cash against an annual operating cash burn of $3.9M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Titan Pharmaceut's Piotroski F-Score?

Titan Pharmaceut (TTNP) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Titan Pharmaceut's earnings high quality?

Titan Pharmaceut (TTNP) has an earnings quality ratio of 0.82x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.